14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.58 $5.85 Friday, 3rd May 2024 CTMX stock ended at $4.43. This is 1.56% less than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 14.22% from a day low at $4.43 to a day high of $5.06.
90 days $1.38 $5.85
52 weeks $1.04 $5.85

Historical CytomX Therapeutics prices

Date Open High Low Close Volume
Mar 30, 2023 $1.52 $1.55 $1.44 $1.48 1 196 007
Mar 29, 2023 $1.54 $1.58 $1.46 $1.54 1 238 150
Mar 28, 2023 $1.48 $1.63 $1.43 $1.52 3 740 527
Mar 27, 2023 $1.75 $1.84 $1.74 $1.79 1 356 645
Mar 24, 2023 $1.70 $1.73 $1.65 $1.70 904 495
Mar 23, 2023 $1.73 $1.76 $1.64 $1.69 1 217 143
Mar 22, 2023 $1.84 $1.84 $1.73 $1.74 916 787
Mar 21, 2023 $1.85 $1.87 $1.77 $1.80 954 783
Mar 20, 2023 $1.90 $1.90 $1.79 $1.84 665 283
Mar 17, 2023 $1.88 $1.92 $1.83 $1.86 1 417 943
Mar 16, 2023 $1.98 $2.02 $1.90 $1.94 814 706
Mar 15, 2023 $2.07 $2.12 $1.99 $2.03 1 067 568
Mar 14, 2023 $2.03 $2.13 $1.97 $2.11 1 997 007
Mar 13, 2023 $1.90 $2.03 $1.88 $1.95 1 854 698
Mar 10, 2023 $1.97 $1.97 $1.80 $1.86 1 605 628
Mar 09, 2023 $2.07 $2.14 $1.93 $1.96 1 347 280
Mar 08, 2023 $2.17 $2.19 $2.07 $2.10 625 730
Mar 07, 2023 $2.08 $2.23 $2.08 $2.17 1 648 202
Mar 06, 2023 $2.14 $2.16 $1.98 $2.08 1 168 365
Mar 03, 2023 $2.15 $2.16 $2.09 $2.14 415 306
Mar 02, 2023 $2.12 $2.16 $2.08 $2.15 467 650
Mar 01, 2023 $2.17 $2.20 $2.15 $2.17 370 126
Feb 28, 2023 $2.14 $2.18 $2.12 $2.15 258 453
Feb 27, 2023 $2.16 $2.23 $2.14 $2.15 532 867
Feb 24, 2023 $2.21 $2.21 $2.12 $2.13 960 095
Click to get the best stock tips daily for free!

About CytomX Therapeutics

CytomX Therapeutics CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme... CTMX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT